DLBCL

>

Latest News

Brentuximab Vedotin Improves Survival in Relapsed/Refractory DLBCL
Brentuximab Vedotin Improves Survival in Relapsed/Refractory DLBCL

March 12th 2024

Findings from the phase 3 ECHELON-3 trial demonstrated that brentuximab vedotin plus lenalidomide and rituximab led to improvements in overall survival among patients with diffuse large B-cell lymphoma.

Utilization Challenges Hold Back the Adoption of Bispecific Therapies
Utilization Challenges Hold Back the Adoption of Bispecific Therapies

February 23rd 2024

Rizzieri Looks at Long-Term Efficacy of Combination Therapy in DLBCL
Rizzieri Looks at Long-Term Efficacy of Combination Therapy in DLBCL

February 17th 2024

What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL
What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL

February 16th 2024

Real-World Data Confirms Efficacy of Tafasitamab for R/R DLBCL
Real-World Data Confirms Efficacy of Tafasitamab for R/R DLBCL

February 8th 2024

Video Series
Video Interviews
Podcasts

More News